ZenBio News & Events
- BioIVT Acquires ZenBio Inc.: Supporting Advancements in Drug Discovery and Cosmetics August 21, 2024
- Dr. John Ludlow Joins ZenBio's Scientific Leadership Team
- ZenBio, Inc. Awarded a Phase I SBIR Grant for the Development of an Islet Drug Discovery Platform
- Awarded a Phase I SBIR Grant For the Development of Drug Discovery Platforms for Diabetes and Obesity
- Human Renal Cell Systems to advance kidney disease research and renal toxicity screening
- ZenBio, Inc. Awarded a Phase I SBIR Grant to Develop Drug Screening Platform with Human Skeletal Muscle Stem Cells
- ZenBio, Inc Awarded Phase II SBIR Grant for Human Breast Cancer Program
- ZenBio, Inc. Awarded Phase I SBIR Grant to Develop Adipose Stem Cells into Insulin Producing Cells
- ZenBio, Inc. Awarded a Phase I SBIR Grant to Develop Novel Human CellBased Models of Fatty Liver Disease
- ZenBio Licenses an Important Cell Line from Harvard to Drive Metabolic Disease Research
- ZenBio and CELLnTEC Partner to Expand Reach in Epithelial Cell Culture Market
- ZenBio, Inc. Awarded a $1.88M Phase II SBIR Grant To Commercialize Primary Human Peritoneal Mesothelial Cells
- ZenBio, Inc. Awarded $1.38 Million Phase II SBIR Grant for Skeletal Muscle Program
- ZenBio Awarded Grant to Provide Human Breast Cancer Cell System
- ZenBio, Inc and Pennington Biomedical Research Center Collaborate to Identify Therapeutic Agents from Natural Products
- ZenBio and Vala Sciences announce SBIR funded collaboration
